|
Herpes Simplex Infections
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Herpes simplex virus (HSV) entry requires the interaction between the envelope glycoprotein D (gD) and a cellular receptor such as nectin-1 (also named herpesvirus entry mediator C [HveC]) or HveA/HVEM.
|
11836420 |
2002 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Herpes simplex virus glycoprotein D interferes with binding of herpesvirus entry mediator to its ligands through downregulation and direct competition.
|
20826693 |
2010 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Herpes simplex virus (HSV) entry into cells is triggered by the binding of envelope glycoprotein D (gD) to a specific receptor, such as nectin-1 or herpesvirus entry mediator (HVEM), resulting in activation of the fusion effectors gB and gH and virus penetration.
|
20861246 |
2010 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Herpes simplex virus entry into cells requires the binding of envelope glycoprotein D (gD) to an entry receptor.
|
21382632 |
2011 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Herpes simplex virus glycoprotein D relocates nectin-1 from intercellular contacts.
|
27723487 |
2016 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Herpes simplex virus glycoprotein D (gD) peptide at the N terminus of AIDSVAX<sup>®</sup> B/E and B/B gp120 proteins induced antibodies in all trials, although significantly higher in VAX trials. gD peptide induced IgA, IgG1, IgG2, and IgG3 but not IgG4.
|
28006952 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Glycoprotein D or J delivered in trans blocks apoptosis in SK-N-SH cells induced by a herpes simplex virus 1 mutant lacking intact genes expressing both glycoproteins.
|
11090178 |
2000 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Glycoprotein D (gD) of herpes simplex virus type 1 (HSV-1) plays a key role in multiple events during infection including virus entry, cell-to-cell spread, and virus-induced syncytia formation.
|
30465930 |
2019 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
A live attenuated HSV virus vaccine, VC2 was compared to a subunit HSV vaccine, glycoprotein D (gD2) administered with the adjuvant, MPL/Alum using the guinea pig model of genital herpes.
|
30917165 |
2019 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
A novel glycoprotein D-specific monoclonal antibody neutralizes herpes simplex virus.
|
29061442 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
A region near the amino terminus (residues 7 to 21) of gD which is recognized by monoclonal antibodies able to neutralize herpes simplex virus in the absence of complement was not essential for function.
|
2157872 |
1990 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Although the reaction of 3-O-sulfation can be catalysed by the largest family of HS sulfotransferases, very few mechanisms have been associated with this modification and to date, only glycoprotein D (gD) of herpes simplex virus-1 (HSV-1 gD) and cyclophilin B (CyPB) have been well-described as ligands for 3-<i>O</i>-sulfated HS.
|
28174681 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Analysis of herpes simplex virus type 1 glycoprotein D nucleotide sequence in human herpes simplex encephalitis.
|
8799220 |
1996 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1.
|
16213178 |
2005 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
As specific RNA template, RNA extracted from stable transfectants ectopically expressing the herpes simplex virus 1 glycoprotein D gene was utilized.
|
28963576 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Binding of herpes simplex virus glycoprotein D to nectin-1 exploits host cell adhesion.
|
22146396 |
2011 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
By this method, the herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) gene was inserted into an intergenic site in the unique short region of the Oka VZV genome.
|
7494331 |
1995 |
|
Herpes Simplex Infections
|
0.100 |
AlteredExpression
|
group |
BEFREE |
DcR3/TR6, a secreted protein belonging to the TNF receptor superfamily, interacts with lymphotoxin-like, exhibits inducible expression, and competes with herpes simplex virus glycoprotein D for herpes virus entrance mediator (LIGHT), Fas ligand (FasL), and TL1A, all members of the TNF superfamily.
|
15814697 |
2005 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
DNA vaccines expressing herpes simplex virus type 2 (HSV-2) full-length glycoprotein D (gD), or a truncated form of HSV-2 glycoprotein B (gB) were evaluated for protective efficacy in two experimental models of HSV-2 infection.Intramuscular (i.m.) injection of mice showed that each construction induced neutralizing serum antibodies and protected the mice from lethal HSV-2 infection.
|
8876149 |
1996 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Earlier this laboratory constructed a herpes simplex virus 1 recombinant (R5111) that carries a IL13 ligand inserted into glycoprotein D and can enter cells via the IL13Ralpha2 receptor commonly expressed on the surface of malignant glioma cells.
|
16292350 |
2006 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Efficient production of recombinant glycoprotein D of herpes simplex virus type 2 in Pichia pastoris and its protective efficacy against viral challenge in mice.
|
27868164 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Evaluation of recombinant adenovirus vaccines based on glycoprotein D and truncated UL25 against herpes simplex virus type 2 in mice.
|
28378925 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of herpes simplex virus glycoprotein D on antigen presenting cells infected with vaccinia recombinants and protective immunity.
|
3263886 |
1988 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Female C57BL/6J mice were immunized rectally (IR) or intramuscularly (IM) with rVCG co-expressing the <i>Chlamydia trachomatis</i> PmpD and PorB proteins (rVCG- PmpD/PorB) with and without FL or glycoprotein D of HSV-2 (rVCG-gD2) as antigen control.
|
31333682 |
2019 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Herein, we report that the live-attenuated herpes simplex virus 1 (HSV-1) VC2 vaccine strain, which has been shown to be unable to enter into neurons and establish latency in mice, can be utilized as a vector for the heterologous expression of EHV-1 glycoprotein D (gD) and that the intramuscular immunization of mice results in strong antiviral humoral and cellular immune responses.
|
28404844 |
2017 |